Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Carcinoma, Non-Small-Cell Lung 12Lung Neoplasms 8Neoplasm Metastasis 6Breast Neoplasms 6Thyroid Neoplasms 4Prostatic Neoplasms 4Neoplasms 4Squamous Cell Carcinoma of Head and Neck 3Urinary Bladder Neoplasms 2Pleural Effusion 2Ovarian Neoplasms 2Kidney Neoplasms 2Fallopian Tube Neoplasms 2Carcinoma, Renal Cell 2Carcinoma, Medullary 2Urethral Neoplasms 1Ureteral Neoplasms 1Thyroid cancer, medullary 1Thyroid Diseases 1Thyroid Cancer, Papillary 1Stomach Neoplasms 1Small Cell Lung Carcinoma 1Relapsed Pediatric Solid Tumor 1Recurrence 1Rectal Neoplasms 1Precancerous Conditions 1Peritoneal Neoplasms 1Pancreatic Neoplasms 1Oligodendroglioma 1Non-small Cell Lung Cancer Metastatic 1

Interventions

Fulvestrant 8olaparib 4Capecitabine 4pyrotinib 3Docetaxel 3toripalimab 2Vinorelbine 2Trastuzumab 2Letrozole 2Injections 2Goserelin 2Alpelisib 2vandetanib 1trastuzumab deruxtecan 1talazoparib 1sacituzumab govitecan 1pembrolizumab 1neratinib 1liposomal doxorubicin 1exemestane 1eribulin 1dalpiciclib 1ceralasertib 1cediranib 1capivasertib 1abemaciclib 1Tablets 1Paclitaxel 1Moxifloxacin 1Lead 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Advanced Breast Cancer × vandetanib × Clear all
NCT00494481 2016-09-30

E3 Breast Cancer Taxotere Combination

Sanofi

Phase 2 Completed
64 enrolled 7 charts
Breast

Advanced Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡